Skip to main content

Rybelsus® 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)

This video discusses the trial-design and outcomes of the PIONEER 2 study. PIONEER 2 was a 52-week, phase 3a, randomized, open-label, multinational trial enrolling 822 adults with type 2 diabetes.

Play
Pause
Skip
Volume
Chapters
Transcript
References
video_su
Fullscreen

Rybelsus® 14 mg vs. Empagliflozin 25 mg (PIONEER 2 Study)

Chapters
Transcript
References

Return to overview

Transcripts

Return to overview

References